Difference between revisions of "Team:Sheffield/episode9"
| Line 275: | Line 275: | ||
<p>Here we discuss further work that future iGEM teams could carry out if they wished to expand on our work, more specifically on how the device would be introduced to the market </p> | <p>Here we discuss further work that future iGEM teams could carry out if they wished to expand on our work, more specifically on how the device would be introduced to the market </p> | ||
| − | |||
| − | |||
<p>Misusing antibiotics and producing a device both require costs. The cost of a device in mass production should hence be modeled. If manufacturing in a large quantity would be more cost-saving than misusing antibiotics, it provides a case for investing. Data on the cost of materials should be collected to enable such calculation.</p> | <p>Misusing antibiotics and producing a device both require costs. The cost of a device in mass production should hence be modeled. If manufacturing in a large quantity would be more cost-saving than misusing antibiotics, it provides a case for investing. Data on the cost of materials should be collected to enable such calculation.</p> | ||
Revision as of 23:06, 18 October 2016
|
THE FUTURE |
|
|---|
STUDYING INTRODUCTION TO THE MARKET
Here we discuss further work that future iGEM teams could carry out if they wished to expand on our work, more specifically on how the device would be introduced to the market
Misusing antibiotics and producing a device both require costs. The cost of a device in mass production should hence be modeled. If manufacturing in a large quantity would be more cost-saving than misusing antibiotics, it provides a case for investing. Data on the cost of materials should be collected to enable such calculation.
Devices like ours that contain GM live bacteria likely require reviews and approval from authorities such as NICE (National Institute for Health and Care Excellence) if they were used in real life applications. Future iGEM teams with similar project should make design decisions accordingly.
In addition to safety, managements of public and private providers should be consulted,for example, NHS(National Health Service) and Bupa, to understand their demand. Business plans should be prepared when meeting with them.
